Business Description
Iovance Biotherapeutics Inc
NAICS : 325411
SIC : 2834
ISIN : US4622601007
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.69 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.13 | |||||
Debt-to-EBITDA | -0.18 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 4.5 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 0.2 | |||||
3-Year EPS without NRI Growth Rate | -0.2 | |||||
3-Year FCF Growth Rate | 3.6 | |||||
3-Year Book Growth Rate | -20.1 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.79 | |||||
Quick Ratio | 2.7 | |||||
Cash Ratio | 2.54 | |||||
Days Inventory | 331.31 | |||||
Days Sales Outstanding | 28.24 | |||||
Days Payable | 961.99 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.4 | |||||
Shareholder Yield % | -14.59 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | -804.54 | |||||
Operating Margin % | -38734.99 | |||||
Net Margin % | -37345.42 | |||||
FCF Margin % | -32305.3 | |||||
ROE % | -73.91 | |||||
ROA % | -57.24 | |||||
ROIC % | -123.45 | |||||
ROC (Joel Greenblatt) % | -257.37 | |||||
ROCE % | -67.53 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2266 | |||||
PB Ratio | 4.96 | |||||
Price-to-Tangible-Book | 8.15 | |||||
EV-to-EBIT | -6.75 | |||||
EV-to-EBITDA | -7.28 | |||||
EV-to-Revenue | 2614.45 | |||||
EV-to-FCF | -7.71 | |||||
Price-to-Net-Current-Asset-Value | 25.82 | |||||
Price-to-Net-Cash | 34.19 | |||||
Earnings Yield (Greenblatt) % | -14.81 | |||||
FCF Yield % | -11.6 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Iovance Biotherapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 1.189 | ||
EPS (TTM) ($) | -1.88 | ||
Beta | 0.03 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR ($) | 0 | ||
20-Day SMA ($) | 24.275 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 24.275 - 24.275 | ||
Shares Outstanding (Mil) | 279.31 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Iovance Biotherapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Iovance Biotherapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Iovance Biotherapeutics Inc Frequently Asked Questions
What is Iovance Biotherapeutics Inc(LTS:0JDK)'s stock price today?
When is next earnings date of Iovance Biotherapeutics Inc(LTS:0JDK)?
Does Iovance Biotherapeutics Inc(LTS:0JDK) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |